ETH Zurich researchers develop electronic implant to lower blood sugar

Researchers at ETH Zurich have developed an experimental electronic implant designed to treat type 2 diabetes and obesity by chemically converting glucose into gluconate. Unlike traditional treatments that rely on insulin delivery, this device uses a small electrical impulse to trigger a reaction on an electrode coated with gold and platinum nanoparticles.

In laboratory studies involving diabetic mice, the implant successfully stabilized glucose levels over a six-week period. Additionally, the treated mice lost approximately 10% of their body weight. The system is designed to operate wirelessly, potentially allowing for remote management via a smartphone and integration with continuous glucose monitors to automate regulation.

While the results are promising, scientists emphasize that the technology has not yet been tested in humans. Significant questions remain regarding whether the implant can safely and effectively process glucose at a scale sufficient to provide clinical benefits in the human body, given the metabolic and immunological differences between mice and humans.